Krystal Biotech Inc | Trend line / H&SNASDAQ:KRYS (Krystal Biotech Inc)
Engages in developing and commercializing pharmaceutical products.
It offers the product, VYJUVEK.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.83 USD
10.93 M USD
50.70 M USD
24.31 M
About Krystal Biotech, Inc.
Sector
Industry
CEO
Krish S. Krishnan
Website
Headquarters
Pittsburgh
Founded
2016
FIGI
BBG00HDGRHH7
Krystal Biotech, Inc. engages in developing and commercializing pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of KRYS is 178.10 USD — it has increased by 1.26% in the past 24 hours. Watch Krystal Biotech, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Krystal Biotech, Inc. stocks are traded under the ticker KRYS.
KRYS stock has fallen by −9.15% compared to the previous week, the month change is a 0.47% rise, over the last year Krystal Biotech, Inc. has showed a 72.03% increase.
We've gathered analysts' opinions on Krystal Biotech, Inc. future price: according to them, KRYS price has a max estimate of 221.00 USD and a min estimate of 195.00 USD. Watch KRYS chart and read a more detailed Krystal Biotech, Inc. stock forecast: see what analysts think of Krystal Biotech, Inc. and suggest that you do with its stocks.
KRYS reached its all-time high on Jul 26, 2024 with the price of 219.34 USD, and its all-time low was 8.03 USD and was reached on Dec 19, 2017. View more price dynamics on KRYS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
KRYS stock is 4.63% volatile and has beta coefficient of 1.89. Track Krystal Biotech, Inc. stock price on the chart and check out the list of the most volatile stocks — is Krystal Biotech, Inc. there?
Today Krystal Biotech, Inc. has the market capitalization of 5.12 B, it has increased by 2.26% over the last week.
Yes, you can track Krystal Biotech, Inc. financials in yearly and quarterly reports right on TradingView.
Krystal Biotech, Inc. is going to release the next earnings report on Mar 3, 2025. Keep track of upcoming events with our Earnings Calendar.
KRYS earnings for the last quarter are 0.91 USD per share, whereas the estimation was 0.99 USD resulting in a −8.40% surprise. The estimated earnings for the next quarter are 1.18 USD per share. See more details about Krystal Biotech, Inc. earnings.
Krystal Biotech, Inc. revenue for the last quarter amounts to 83.84 M USD, despite the estimated figure of 82.94 M USD. In the next quarter, revenue is expected to reach 91.55 M USD.
KRYS net income for the last quarter is 27.18 M USD, while the quarter before that showed 15.57 M USD of net income which accounts for 74.59% change. Track more Krystal Biotech, Inc. financial stats to get the full picture.
No, KRYS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 229.00 employees. See our rating of the largest employees — is Krystal Biotech, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Krystal Biotech, Inc. EBITDA is 71.54 M USD, and current EBITDA margin is −181.90%. See more stats in Krystal Biotech, Inc. financial statements.
Like other stocks, KRYS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Krystal Biotech, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Krystal Biotech, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Krystal Biotech, Inc. stock shows the buy signal. See more of Krystal Biotech, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.